Tumor immunotherapy has become an important adjuvant therapy after surgery, radiotherapy, and chemotherapy. In recent years, the role of tumor-associated antigen (TAA) in tumor immunotherapy has become increasingly prominent. Cancer-testis antigen (CTA) is a kind of TAA that is highly restricted in a variety of tumors and can induce an immune response. The expression of CTA affects the occurrence, development, and prognosis of ovarian cancer and is closely related to tumor immunity. This review outlines a comprehensive of overview the regulatory mechanism, immunogenicity, clinical expression significance, tumorigenesis, and application prospects of CTA in ovarian cancer, all of which can provide novel insights in the improvement of diagnosis and treatment for ovarian cancer.